Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy

Dohner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 129, 424, 10.1182/blood-2016-08-733196 Sorror, 2017, Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality, JAMA Oncol, 3, 1675, 10.1001/jamaoncol.2017.2714 Grimwade, 2014, Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?, Blood, 124, 3345, 10.1182/blood-2014-05-577593 Jongen-Lavrencic, 2018, Molecular minimal residual disease in acute myeloid leukemia, N Engl J Med, 378, 1189, 10.1056/NEJMoa1716863 Milano, 2016, Cord-blood transplantation in patients with minimal residual disease, N Engl J Med, 375, 944, 10.1056/NEJMoa1602074 Yin, 2012, Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, 120, 2826, 10.1182/blood-2012-06-435669 Jourdan, 2013, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, 121, 2213, 10.1182/blood-2012-10-462879 Zhu, 2013, MRD-directed risk stratification treatment may improve outcomes of t(8.21) AML in the first complete remission: results from the AML05 multicenter trial, Blood, 121, 4056, 10.1182/blood-2012-11-468348 Ivey, 2016, Assessment of minimal residual disease in standard-risk AML, N Engl J Med, 374, 422, 10.1056/NEJMoa1507471 Balsat, 2017, Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group, J Cliln Oncol, 35, 185, 10.1200/JCO.2016.67.1875 Chen, 2015, Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia, J Clin Oncol, 33, 1258, 10.1200/JCO.2014.58.3518 Araki, 2016, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?, J Clin Oncol, 34, 329, 10.1200/JCO.2015.63.3826 Freeman, 2018, Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations, J Clin Oncol, 36, 1486, 10.1200/JCO.2017.76.3425 Morita, 2018, Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia, J Clin Oncol, 36, 1788, 10.1200/JCO.2017.77.6757 Maurillo, 2008, Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia, J Clin Oncol, 26, 4944, 10.1200/JCO.2007.15.9814 Versluis, 2017, Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission, JCO Precis Oncol, 1 Brunstein, 2010, Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood, Blood, 116, 4693, 10.1182/blood-2010-05-285304 Scott, 2017, Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, J Clin Oncol, 35, 1154, 10.1200/JCO.2016.70.7091 Festuccia, 2016, Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome, Biol Blood Marrow Transplant, 22, 1227, 10.1016/j.bbmt.2016.03.029 Rashidi, 2016, Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials, Blood, 128, 763, 10.1182/blood-2016-03-674127 Chapuis, 2013, Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients, Sci Transl Med, 5, 10.1126/scitranslmed.3004916